Navigation Links
Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody
Date:10/2/2008

t of cancer through its affinity for a novel target, lactadherin. Lactadherin is an extracellular matrix protein that is released by numerous types of tumor cells, including most breast cancers, ovarian cancers and prostate cancer. Lactadherin has a critical role in promoting the growth of new blood vessels to support tumor growth through the activation of VEGF-mediated angiogenesis. The target lactadherin and Angiolix are supported and protected by granted patents.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill cancer cells; Alchemix, a chemotherapeutic agent that combines multiple modes of action to overcome drug resistance. Access is also developing Phenylbutyrate ("PB"), an HDAC inhibitor and differentiating agent currently a Phase 2 clinical candidate. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our ability to close the financing
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
2. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
3. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
11. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... , Aug. 1, 2014 MGC ... technologies company, announced today that it has completed ... manufacturer of cardiorespiratory diagnostic products based in Sorinnes, ... has served the European cardiorespiratory diagnostics market since ... revenues of approximately €4.7 million ($6.3 million) and ...
(Date:8/1/2014)... , Aug. 1, 2014  NxStage Medical, Inc. (Nasdaq: ... today announced that Jeffrey H. Burbank , Chief Executive ... present at the 34 th Annual Canaccord Genuity Growth ... MA , on Wednesday, August 13 th at ... made available at http://ir.nxstage.com/ .  About ...
(Date:8/1/2014)... -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) announced ... evaluating ISIS-SMN Rx in infants with spinal muscular ... mortality. Isis plans to dose the first infant in ... time Isis will earn an $18 million milestone payment ... study, ENDEAR, is the first of several planned studies ...
Breaking Medicine Technology:MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 2MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 3MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 4NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 2Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 3Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 4Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 5
... - First prospective biomarker trial in non-small cell ... /PRNewswire-FirstCall/ -- Response,Genetics, Inc. today announced that positive ... issue of the Journal of Clinical,Oncology suggests that ... in patient biopsies,with advanced non-small cell lung cancer ...
... been,specifically designed by scientists to be safe to normal ... a preliminary study,researchers said today at the ESMO Conference ... type of herpes simplex virus,modified so that it selectively ... "It doesn't replicate in normal, healthy cells, so our ...
Cached Medicine Technology:Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 2Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 3Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 4MediGene Announces Cancer-Fighting Virus Shows Promise in Early,Clinical Trial 2MediGene Announces Cancer-Fighting Virus Shows Promise in Early,Clinical Trial 3MediGene Announces Cancer-Fighting Virus Shows Promise in Early,Clinical Trial 4MediGene Announces Cancer-Fighting Virus Shows Promise in Early,Clinical Trial 5
(Date:8/1/2014)... York City, NY (PRWEB) August 01, 2014 ... for two incomes, and the convenience of processed, microwavable dinners, ... epidemic. Diet Doc does not offer patients a mere quick ... about helping everyone, in any part of the country, get ... that if they offer patients the tools and education on ...
(Date:8/1/2014)... Pompano Beach, FL (PRWEB) August 01, 2014 ... capsules, announced today the opening of a new ... Canada. , The company announced expansion plans last ... products. According to Dale Martin, General Manager, “KCAPS® ... around the world.” He added that: “Compared to ...
(Date:8/1/2014)... St. Christopher's Hospital for Children announced that they ... with Ed Begley Jr, airing later this year 2014, ... St. Christopher's Hospital for Children offers a wide range ... 21 years of age. With over 220 pediatric specialists, ... autism and childhood obesity. , “St. Christopher’s is ...
(Date:8/1/2014)... 01, 2014 A new study ... carbohydrates may contribute to the development of colorectal cancer ... disease. The study was authored by Alberto Martin of ... to cause intestinal cells to multiply and create tumors ... cancer. , “What’s interesting about this study,” said ...
(Date:8/1/2014)... For many people, forgetfulness becomes more ... within the normal range, slips that seem new or ... This merits a closer look, not a panic attack, ... Harvard Men's Health Watch . , "We don't ... their keys are they are on the path to ...
Breaking Medicine News(10 mins):Health News:Diet Doc Medical Weight Loss Programs Announces Diet Plans That Melt Excess Fat Rapidly While Teaching Patients How to Avoid Obesity 2Health News:Diet Doc Medical Weight Loss Programs Announces Diet Plans That Melt Excess Fat Rapidly While Teaching Patients How to Avoid Obesity 3Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 2Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 3Health News:Carbs May Contribute to Colon Cancer 2Health News:Worried About Changes in Your Memory? It's Worth A Closer Look, From the August 2014 Harvard Men's Health Watch 2
... brain scans to try and study the biology of dread. ... brain pays to the expected pain // determines and whether ... that simple diversions could alleviate the misery. ,The ... new field called neuroeconomics that uses brain imaging to try ...
... Baeg Moon-hong. He is a senior researcher at the Korea ... was show cased in an exhibition at the Seoul Education ... meters tall. The special features are that it can understand ... expressions. , The first android was made by ...
... the shaking leg syndrome is a common type of disorder in ... For the first time Europe has approved the drug to be ... aches and pains. Statistics show that about 10% of the people ... by the European Medicines Agency. As of now it is used ...
... Health conscious people here lawyers in California have sued PepsiCo ... benzene//., ,The drink in question is Pepsi Twist drink, ... three' soft drinks firms has been drawn into a legal ... the lawsuit, "Pepsi Twist has been falsely promoted as a ...
... the Supreme Court Friday reversed an earlier order directing ... all-India basis// for scheduled castes and scheduled tribes candidates ... ,A bench of judges K.G. Balakrishnan, A.R. Lakshmanan ... General Gopal Subramaniam that enforcing the 10 percent quota ...
... kid of Orissa, declared that his health is normal. // ... up after he ran an astounding 65km earlier this week. ... at Bhubaneswar for a medical check up on the orders ... coach Biranchi Das was exploiting the boy for his personal ...
Cached Medicine News:Health News:Supreme Court Quashed Reservation Quotas For PG Medical Courses 2Health News:Marathon Kid Budhia’s Health Not Compromise 2
...
...
EDM Lumbar Drainage Kit with and without Bioglide are fabricated of radiopaque (barium impregnated) silicone tubing, and are packaged with stainless steel stylets inserted in the lumen....
Medtronic neurosurgery external drainage and monitoring (EDM) products meet a variety of needs for CSF drainage and monitoring....
Medicine Products: